GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,352.20
-0.80 (-0.06%)
As of 2:04PM GMT. Market open.
Stock chart is not supported by your current browser
Previous Close1,353.00
Open1,356.60
Bid1,351.80 x 175400
Ask1,352.20 x 417900
Day's Range1,349.20 - 1,360.80
52 Week Range1,270.00 - 1,724.50
Volume4,255,867
Avg. Volume10,515,815
Market Cap65.657B
Beta1.15
PE Ratio (TTM)28.59
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.01 (5.14%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
    Zacksyesterday

    Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

    Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.

  • Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
    Zacks4 days ago

    Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

    Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

  • Reuters7 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Reuters7 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In
    Bloomberg7 days ago

    Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In

    CEO Walmsley has reshuffled 40 percent of top managers to spark innovation

  • What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?
    Simply Wall St.7 days ago

    What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?

    GlaxoSmithKline plc’s (LSE:GSK) latest earnings update in September 2017 confirmed that the company faced a immense headwind with earnings falling by -89.17%. Below, I’ve laid out key growth figures onRead More...

  • The Wall Street Journal7 days ago

    Rivals Help Fund Regeneron’s Gene-Sequencing Effort

    Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.

  • Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
    Bloomberg8 days ago

    Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth

    GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.K.’s largest drugmaker, replacing about 50 of the top 125 managers since taking over last year.

  • 1 Reason Dynavax Technologies Corporation Stock Soared in 2017
    Motley Fool8 days ago

    1 Reason Dynavax Technologies Corporation Stock Soared in 2017

    Thanks to the FDA approval of its hepatitis B vaccine, Dynavax's shares crushed the broader market in 2017.

  • American City Business Journals11 days ago

    Outspoken biotech CEO Paul Hastings leaves Peninsula company (Video)

    Paul Hastings, the energetic and outspoken chairman, president and CEO of OncoMed Pharmaceuticals Inc., stepped down this week, the company said. Hastings, who in September took a medical leave of absence following a string of clinical setbacks in the Redwood City company's drug portfolio and the layoff of 60 employees, wasn't immediately available to comment. The company disclosed the news Thursday, but said Hastings' resignation was effective Monday.

  • Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?
    Investor's Business Daily13 days ago

    Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?

    Spark and GlaxoSmithKline are pricing the world's first approved gene therapies at prices approaching $1 million.

  • U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy
    Bloomberg14 days ago

    U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy

    The U.K.’s thrifty health authority has cleared its most expensive medicine ever -- a $700,000 GlaxoSmithKline Plc treatment for an illness known as “bubble-boy disease.” But the overall cost to the country’s ...

  • 3 Top Dividend Stocks With Yields Over 4%
    Motley Fool16 days ago

    3 Top Dividend Stocks With Yields Over 4%

    High-yield stocks have gotten harder to find in the current bull market, but these three should please even the pickiest income investors.

  • Benzinga16 days ago

    Barron's Picks And Pans: Chevron, Corning, GlaxoSmithKline And More

    This weekend's Barron's examines why things may be looking up for one big oil company. Other featured articles offer the prospects for a big drug maker facing stiff competition and a glassmaker that may ...

  • Barrons.com17 days ago

    [$$] Glaxo: Expect a Speedy Recovery

    Advair, the world’s top-selling respiratory drug, will probably face generic competition in the U.S. beginning in 2018. It’s the biggest moneymaker for United Kingdom-based GlaxoSmithKline , whose earnings estimates have been sliding, and whose shares have tumbled since the summer. To see why, look back to Pfizer (PFE) seven years ago, on the eve of Lipitor’s patent expiration.

  • GuruFocus.com19 days ago

    GlaxoSmithKline Is a Massive Bargain

    Wide moat and low price equals deep discounts for investors

  • Market Realist21 days ago

    Measuring Sanofi’s Valuation This December

    For 3Q17, Sanofi reported revenues of 9.05 billion euros—a 4.7% YoY (year-over-year) rise in operating revenues, compared with 9.03 billion in 3Q16.

  • Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?
    Simply Wall St.22 days ago

    Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?

    GlaxoSmithKline plc (LSE:GSK) is trading with a trailing P/E of 27.2x, which is higher than the industry average of 25.7x. While GSK might seem like a stock to avoid orRead More...

  • Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
    Motley Fool25 days ago

    Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

    Which stock wins in a head-to-head match-up between these two big drugmakers?

  • 3 High-Yield Stocks Still Worth Buying
    Motley Fool28 days ago

    3 High-Yield Stocks Still Worth Buying

    All three companies pay at least double the average yield of the S&P 500.

  • Reuters29 days ago

    GlaxoSmithKline boosts stake in Saudi Arabia unit

    British drugmaker GlaxoSmithKline (GSK.L) (GSK) said on Monday it has boosted its stake in its Saudi Arabian unit to 75 percent as it seeks to benefit from the kingdom's plan to transform the economy and raise local manufacturing of pharmaceutical products. Before the acquisition, GSK owned 49 percent of Glaxo Saudi Arabia, a business it formed in 1992 with local partner Banaja KSA Holding Company. "The acquisition represents a step forward towards the strengthening of our operations in the kingdom," said Andrew Miles, vice president and general manager of GSK in the Gulf Cooperation Council states.

  • GuruFocus.comlast month

    Stocks That Fell to 3-Year Lows in the Week of Dec. 15

    General Electric Co. (GE), GlaxoSmithKline PLC (GSK), Ferrellgas Partners LP (FGP) and Crescent Point Energy Corp. (CPG) have declined to their respective three-year lows.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkeylast month

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • GSK CEO: Our top priority is to invest in growth in our c...
    CNBC Videos8 days ago

    GSK CEO: Our top priority is to invest in growth in our c...

    Emma Walmsley, GlaxoSmithKlein CEO, speaks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about reshaping the company and her outlook for 2018.

  • GSK's history spans three centuries and started in three ...
    CNBC Videos28 days ago

    GSK's history spans three centuries and started in three ...

    GSK has roots in the UK, US and New Zealand. 300 years later, mergers and acquisitions has made it the healthcare and pharmaceutical company it is today.